Phase 3
40 Years
65 Years
40 Years
65 Years
Not Enrolling
Male
Abdominal Obesity, Metabolic Syndrome, Obesity
Male
Abdominal Obesity, Metabolic Syndrome, Obesity
Trial Information
Inclusion Criteria:
- Fasting plasma glucose level ≥ 6.1 and ≤ 7.8 mmol/L (IFG) and/or a plasma glucose 2
hours after a 75g oral glucose load between 6.9-11.0 mmol/L (IGT).
- BMI > 25 kg/m2.
- Waist/hip ratio > 0.95
Exclusion Criteria:
- Proliferative diabetic retinopathy.
- Macro-albuminuri and/or serum creatinine >150mmol/L
- Known ischemic heart disease, previous stroke or claudicatio intermittence.
- Known malignancy.
- Other hormonal therapy.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
Glucose tolerance
Outcome Time Frame:
Baseline, 3, 6 and 12 months
Safety Issue:
No
Authority:
Sweden: Medical Products Agency
Study ID:
GHNIDDM
NCT ID:
NCT00781547
Start Date:
January 1999
Completion Date:
May 2005
Related Keywords:
- Abdominal Obesity
- Metabolic Syndrome
- Obesity
- growth hormone
- obesity
- abdominal obesity
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Obesity
- Obesity, Abdominal
- Metabolic Syndrome X
Name | Location |
|---|
